Kevzara is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs (DMARDs). Kevzara is also referred to by its drug name, sarilumab.
Kevzara is considered a biologic DMARD. Kevzara is a genetically engineered protein. Kevzara is believed to work by inhibiting interleukin (IL)-6, a chemical messenger involved in autoimmune attacks. Kevzara prevents IL-6 from signaling the immune system to attack the tissues.
How do I take it?
Kevzara is administered once every two weeks by subcutaneous injection.
Kevzara is available as a prefilled, single-use syringe or pen.
The FDA-approved label for Kevzara lists common side effects including increased liver enzyme levels, injection site redness, respiratory infections, and urinary tract infections.
Rare but serious side effects listed for Kevzara include severe infections, low blood cell counts, stomach and intestinal damage, severe allergic reactions, and tuberculosis.
For more details about this treatment, visit:
Kevzara — Sanofi
Sarilumab (Kevzara) — American College of Rheumatology
We never share your personal information with anyone.